GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 35 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,337,695 | +107.2% | 10,881,144 | +174.1% | 3.43% | +228.8% |
| Q2 2023 | $15,123,517 | +455.4% | 3,969,427 | +171.1% | 1.04% | +452.4% |
| Q1 2023 | $2,723,008 | +123057.3% | 1,463,983 | +52.3% | 0.19% | -25.9% |
| Q4 2022 | $2,211 | -99.9% | 961,358 | -0.0% | 0.26% | -25.4% |
| Q3 2022 | $3,096,000 | -41.4% | 961,359 | 0.0% | 0.34% | -35.6% |
| Q2 2022 | $5,287,000 | +136.0% | 961,359 | 0.0% | 0.53% | +244.8% |
| Q1 2022 | $2,240,000 | -61.4% | 961,359 | 0.0% | 0.15% | -56.0% |
| Q4 2021 | $5,807,000 | -56.4% | 961,359 | 0.0% | 0.35% | -41.6% |
| Q3 2021 | $13,334,000 | -22.8% | 961,359 | -27.6% | 0.60% | -19.8% |
| Q2 2021 | $17,267,000 | -26.4% | 1,328,257 | -12.8% | 0.75% | -9.3% |
| Q1 2021 | $23,454,000 | – | 1,522,994 | – | 0.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 10,881,144 | $31,337,695 | 3.43% |
| Sio Capital Management, LLC | 2,081,216 | $5,993,902 | 1.86% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,375,000 | $3,960,000 | 1.58% |
| TCG Crossover Management, LLC | 3,038,889 | $8,752,000 | 1.29% |
| Logos Global Management LP | 2,525,000 | $7,272,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,531,497 | $4,410,711 | 0.80% |
| Orbimed Advisors | 9,308,726 | $26,809,131 | 0.57% |
| GREAT POINT PARTNERS LLC | 579,667 | $1,669,441 | 0.30% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $28,517,587 | 0.17% |
| TANG CAPITAL MANAGEMENT LLC | 159,087 | $458,171 | 0.06% |